CN1240392C - Agent for promoting cell activation for external use - Google Patents
Agent for promoting cell activation for external use Download PDFInfo
- Publication number
- CN1240392C CN1240392C CNB031088236A CN03108823A CN1240392C CN 1240392 C CN1240392 C CN 1240392C CN B031088236 A CNB031088236 A CN B031088236A CN 03108823 A CN03108823 A CN 03108823A CN 1240392 C CN1240392 C CN 1240392C
- Authority
- CN
- China
- Prior art keywords
- cell
- skin
- external agent
- cell activation
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000020411 cell activation Effects 0.000 title claims description 15
- 230000001737 promoting effect Effects 0.000 title 1
- 150000004676 glycans Chemical class 0.000 claims abstract description 17
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 17
- 239000005017 polysaccharide Substances 0.000 claims abstract description 17
- 229920002000 Xyloglucan Polymers 0.000 claims abstract description 13
- 108010001062 polysaccharide-K Proteins 0.000 claims abstract description 12
- 229920001543 Laminarin Polymers 0.000 claims abstract description 11
- 239000007864 aqueous solution Substances 0.000 claims abstract description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 10
- 239000008103 glucose Substances 0.000 claims abstract description 10
- 229920001491 Lentinan Polymers 0.000 claims abstract description 7
- 229940115286 lentinan Drugs 0.000 claims abstract description 7
- 239000001814 pectin Substances 0.000 claims abstract description 7
- 229920001277 pectin Polymers 0.000 claims abstract description 7
- 235000010987 pectin Nutrition 0.000 claims abstract description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 6
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 12
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 claims description 10
- 239000005717 Laminarin Substances 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 229920001503 Glucan Polymers 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 13
- 210000002850 nasal mucosa Anatomy 0.000 abstract description 10
- 210000000214 mouth Anatomy 0.000 abstract description 9
- 208000003265 stomatitis Diseases 0.000 abstract description 7
- 230000001413 cellular effect Effects 0.000 abstract description 6
- 210000001519 tissue Anatomy 0.000 abstract description 6
- 210000004761 scalp Anatomy 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract 2
- 229920002307 Dextran Polymers 0.000 abstract 1
- 229920001218 Pullulan Polymers 0.000 abstract 1
- 239000004373 Pullulan Substances 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 abstract 1
- 235000019423 pullulan Nutrition 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 26
- 238000011282 treatment Methods 0.000 description 18
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 16
- 206010048908 Seasonal allergy Diseases 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 15
- 210000004927 skin cell Anatomy 0.000 description 9
- 230000036039 immunity Effects 0.000 description 8
- 201000004384 Alopecia Diseases 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000003676 hair loss Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000003204 osmotic effect Effects 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 201000004647 tinea pedis Diseases 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 208000035985 Body Odor Diseases 0.000 description 3
- 206010055000 Bromhidrosis Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000003722 extracellular fluid Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 206010067409 Trichophytosis Diseases 0.000 description 1
- 241001148683 Zostera marina Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- -1 glucosan and glucose Chemical class 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to external preparations for enhancing cell activity which comprise polysaccharides dissolved in an aqueous solution. Based on the total weight, 1 to 50% of xyloglucan, 1 to 50% of laminaran and 1 to 50% of krestin are added. The aqueous solution having the polysaccharides dissolved therein further contains, based on the total weight, 1 to 50% of pectin, 1 to 30% of dextran, 1 to 30% of glucose, 1 to 40% of pullulan, 1 to 30% of lentinan, 1 to 50% of cyclodextrin and 1 to 50% of trehalose. These preparations enhance the immune resistance and healing capacity of cell tissues in the oral cavity, nasal mucosa, etc. without any fear of side effect. Thus, they are applicable not only to pollenosis and stomatitis but also to various diseases at the cellular level over a wide scope including the skin and scalp.
Description
Technical field
The present invention relates to promote the external agent of cell activation, this external agent mainly has good remission effect to various diseases such as pollinosis or stomatitis, utilize the electrolyte balance and the osmotic pressure balance of cell to make cell activation simultaneously, and then alleviate the low and various diseases that causes of the cell function of Skin Cell.
Background technology
Be extensive use of the adulterant as various cosmetics or medical external agent such as natural sugar such as inorganic salt, glucose such as sodium chloride or blood plasma in the past.For example, No. 3574854 communiques of United States Patent (USP) have been put down in writing the gentle skin frost that contains sodium chloride etc.Put down in writing the skin cleaning article that contains mineral salts in the description that No. the 3327840th, the open communique of DRP.Put down in writing in No. 3859436 communiques of United States Patent (USP) to use and be mixed with glucose etc. has the sugared composition of lubrication to skin technical scheme.In addition, put down in writing to shave in No. 3777597 communiques of United States Patent (USP) and used glucan aqueous solution.
Yet; even these traditional external agent have the effect of skin sterilization and protection skin; but be difficult to alleviate dermatosis because of the skin capillary tube circulates and hypofunction caused; that is, pigementation, tinea pedis, tinea cruris, trichophytosis, bromhidrosis, baldness, the dandruff, the Skin Cell division such as itch and various diseases that function reduction is caused.
Therefore; the present inventor has invented and can activate Skin Cell; alleviation is because of the low various diseases that causes of the cell function of Skin Cell; can form the environment identical at skin surface, and can utilize electrolyte balance and the promotion of osmotic pressure balance to comprise the aqueous skin and the hair cosmetic composition (No. the 1597430th, patent) of the obstacle cell normalization of skin surface with the Skin Cell interstitial fluid.
This aqueous skin and hair cosmetic composition can stimulate subcutaneous cell to make its division when brown patch occurring and blushing phenomenon and then play therapeutical effect.The effect that scalp and bromhidrosis etc. are then stimulated hair follicle and then obtain to promote hair growth and go bromhidrosis by the osmotic pressure effect.That is, this aqueous skin and hair cosmetic composition are 83% to the treatment rate of baldness, are 95% to the sedimentary treatment rate of pigment, are 53% to the treatment rate of the disease of blushing.
Yet these effects are primarily aimed in skin or hair.The present inventor wishes to activate Skin Cell etc., makes mucomembranous cell activation under the condition that has no side effect, and is effective for stomatitis that is caused because of the oral mucosa disease or the treatment of diseases such as pollinosis that caused because of the nasal mucosa obstacle.
Therefore, the present inventor has invented a kind of external agent that promotes cell activation, and this external agent has no side effect when using as the external agent of oral cavity or nasal mucosa.For example, be applicable to the various diseases (No. the 2681527th, patent) of the cellular level of wider ranges such as stomatitis or pollinosis.The external agent of this promotion cell activation is to have added polysaccharides such as glucosan and glucose, α-1,3-1, the reagent of 6-glucosan, lentinan etc.The external agent of this promotion cell activation is 100% to the treatment of stomatitis, is 100% to the treatment rate of pollinosis.
Yet the external agent of above-mentioned promotion cell activation shows during with 40 artificial objects the treatment rate of pollinosis.Along with pollinosis patient's rapidly increase, the treatment rate of pollinosis there is the tendency that reduces gradually thereafter.That is, originally in the potency test of (putting down into 2 years), pollinosis is shown 100% treatment rate, pass through many decades thereafter, the burst of its treatment rate and sickness rate increases inversely proportional decline rapidly at present.Though the pathogenic factor of pollinosis is not clear and definite, infer that to be individual reason make any difference and bring out this disease the cell of oral cavity or nasal mucosa etc.Therefore, can infer that desire improves the immunity or the recovery from illness ability of oral cavity or nasal mucosa etc., must keep the health status of cell tissue, prevent the harmful effect that various factors causes, take this morbidity of the pollinosis that suppresses to increase rapidly, manifest therapeutic effect simultaneously.
The invention provides a kind of to carried out the external agent of improvement as the external agent of the promotion cell activation of prior art.This external agent can improve the immunity or the recovery from illness ability of oral cavity or nasal mucosa etc., and has no side effect, and is not only applicable to the treatment of pollinosis or stomatitis, also is applicable to the treatment of various diseases of the cellular level of wider ranges such as other skins or scalp.
Summary of the invention
In order to achieve the above object, the present invention relates to the external agent of promotion cell activation that the water-soluble solution of polysaccharide is obtained, in the overall weight ratio, 1～50% xyloglucan, 1～50% laminarin and 1～50% krestin have been added in this aqueous solution.
In the above-mentioned aqueous solution that dissolves polysaccharide, in the overall weight ratio, contain 1～50% pectin, 1～30% glucosan, 1～30% glucose, 1～40% toughness polysaccharide, 1～50% cyclodextrin, 1～30% lentinan and 1～50% trehalose.
In the above-mentioned aqueous solution that dissolves polysaccharide,, also can add 0.1～1% sodium chloride, 0.1～1% calcium chloride and 0.1～1% potassium chloride in the overall weight ratio.
Cause as various symptoms such as the inflammation of human skin pathological changes, pigementation, alopecias is relevant with various factorss such as ultraviolet, chemical substances, and its essence that is limited to the variation of cellular level is as the grain line body film of one of organella in the cell and the obstacle of cell membrane.That is, the obstacle trigger cell internal respiration of grain line body film is obstructed, and then reduces the generation as the ATP (adenosine triphosphate) of cell energy.Because of the decline of the not enough trigger cell film energy transportation function of ATP, thereby reduce mass transport ability between cell and interstitial fluid.Consequently, cause the deficiency of nutrient substance such as glucose in the cell, and then the appearance circulation relevant with the acidity decline of ATP is not good.
The reason that produces the variation of above-mentioned cellular level has many, and particularly for the cell of oral cavity or nasal mucosa etc., the osmotic pressure effect can increase interstitial cell fluid, makes the cell activation of disease location.And,, can improve the immunity or the recovery from illness ability of the cell tissue of oral cavity or nasal mucosa etc. by adding xyloglucan, laminarin and krestin.
The specific embodiment
The basic proportioning of external agent of the present invention is in being dissolved with the aqueous solution of polysaccharide, in the overall weight ratio, and the xyloglucan of interpolation 1～50%, 1～50% laminarin and 1～50% krestin.
Xyloglucan is the sugar chain that is prevalent in the cell wall (wall) of the loose plant cell of elongation.Floristic specificity produces because of galactose or fucose-galactose combine with xylose residues.Though it is this galactose residue and fucosyl residues can combine with lectins respectively, then unknown to the function of these branch sugar chains.The growth of plant cell produces because of the suction phenomenon from the osmotic pressure that cell had, and water absorbing force then causes that by the lax of cell wall the wall pressure minimizing is produced.Though the lax reason of cell wall is unknown, the elongation regular meeting of cell causes the decomposition and the dissolving of xyloglucan, and it is gazed at as one of polysaccharide of managing cellular physiological activity.
Laminarin is classified as the beta glucan of one of carbohydrate, is included in based on zostera marina apoplexy due to endogenous wind such as the Mushrooms of Lentinus Edodes or Thallus Laminariae (Thallus Eckloniae)s, and it has the effect that improves immunity.Known its is difficult to be absorbed separately, must be ingested with protein.
The immunization therapy pharmaceuticals that krestin can be used as the antigenic performance of HLA grade I that strengthens the human cancer cell use, can the former mushroom fungus filament extraction from the river.This krestin has been identified the immunity of tumor diseases such as gastric cancer, colorectal carcinoma, small cell lung cancer and has treated useful.
The present inventor comforms the more in the saccharide, pick out the composition that is applicable to the external agent, consequently, be used in combination xyloglucan, laminarin and krestin, can modulate the external agent of the immunity or the recovery from illness ability of the cell tissue that can improve oral cavity or nasal mucosa etc.
Dissolved in the aqueous solution of above-mentioned polysaccharide,, contained 1～50% pectin, 1～30% glucosan, 1～30% glucose, 1～40% toughness polysaccharide, 1～30% lentinan and 1～50% trehalose in advance in the overall weight ratio.
Pectin is to combine with other compositions as cellulose of the constituent of plant cell wall etc. and make the bonded material of plant cell.It has the effect of gel, can be used as the additive of external agent of the present invention.
Dissolved in the aqueous solution of polysaccharide and also can add sodium chloride, calcium chloride and potassium chloride again.The proportional quantity of sodium chloride is effective to the permeability balance and the electrolyte balance of skin.That is, for making the Skin Cell activation, in the overall weight ratio, its content is 0.1～1%, similarly can dissolve 0.1～1% calcium chloride and 0.1～1% potassium chloride in aqueous solution.
By exemplifying prescription example and pharmacological test example external agent of the present invention is specifically described.
Prescription example 1
Glucosan 18
Glucose 10
Cyclodextrin 2
Trehalose 3
Toughness polysaccharide 7
Lentinan 7
Laminarin 2
Krestin 1
Pectin 3
Xyloglucan 1
Sodium chloride 0.9
Calcium chloride 0.3
Potassium chloride 0.3
Purified Water 44.5
Amount to (weight ratio %) 100
So-called water-phase component (pure water) is the water of the no oil condition made with pure water, does not contain fully that employed water solublity oil is a surfactant etc. when making external agent commonly used such as cosmetics.Therefore, when mixing mentioned component and water-phase component, dissolve fully for making mentioned component, operative temperature is preferably 50～100 ℃.
Table 1 is depicted as the effect of prescription example 1.
Table 1
| Disease name | The object number | Effectiveness (point) | Effective percentage (%) |
| Male baldness | 60 | 118 | 98 |
| The body and mind baldness | 50 | 60 | 60 |
| Acne | 30 | 58 | 97 |
| The disease of blushing | 60 | 66 | 55 |
| Tinea pedis | 50 | 95 | 95 |
| Seborrheic dermatitis | 100 | 197 | 99 |
| Atopic dermatitis | 100 | 98 | 49 |
| Stomatitis | 50 | 100 | 100 |
| Pollinosis | 100 | 196 | 98 |
Table 1 is depicted as the result of the pharmacological testing of prescription example 1.The effectiveness of this moment is meant the effect of using after the external agent of the present invention, and no change is 0 point, and it is 1 point that the recovery from illness tendency being arranged, and efficiency confirmed, and fruit is 2 points, calculates each one total point, and with following formula: effectiveness is calculated in effective percentage=total point/(object number * 2) * 100.This test is used in particular for confirming the therapeutic effect of pollinosis, calculates effective percentage with 100 patients as object.
Consequently, the treatment effective percentage for 100 people's pollinosis reaches 98%.Originally in the test of (putting down into 2 years), though the treatment effective percentage of pollinosis is reached 100%, to today, the burst increase of its treatment effective percentage and sickness rate is inversely proportional to and descends rapidly through many decades.So it is what is worth mentioning that the present invention can keep 98% effective percentage.Again, in 600 cases, confirm side effect not occur, and extremely useful to the disease of very difficult treatment such as male baldness, acne, tinea pedis, seborrheic dermatitis.
Proportioning by prescription example 2 modulates external agent of the present invention.
Prescription example 2
Bextran 45
Glucose 3
Cyclodextrin 2
Trehalose 3
Toughness polysaccharide 3
Lentinan 3
Laminarin 2
Krestin 1
Pectin 3
Xyloglucan 50
Sodium chloride 0.4
Calcium chloride 0.3
Potassium chloride 0.3
Purified Water 25
Amount to (weight ratio %) 100
Consequently, if more than the concentration of xyloglucan is increased to shown in the prescription example 2, the isolating phenomenon in dissolving back then can occur, undesirable as prescription.Again, except xyloglucan, the wantonly a kind concentration in laminarin and the krestin all must reach more than 1% at least just can show effectiveness, if but concentration surpasses 50%, then can't finish prescription.
The present invention by in water-phase component, add in overall weight than 1～50% xyloglucan, 1～50% laminarin and 1～50% krestin, can improve the immunity or the recovery from illness ability of the cell tissue of oral cavity or nasal mucosa etc., the disease that individual factors such as pollinosis are caused has therapeutic effect.
Again; in immunity that improves cell tissue or recovery from illness ability; can form the environment identical with the Skin Cell interstitial fluid; the cell internal respiration obstacle that prevention grain line body film obstacle is caused or produce as the ATP (adenosine triphosphate) of cell energy descends; also can keep electrolyte balance and osmotic pressure balance; and the normalization of the obstacle cell on promotion Skin Cell or mucomembranous cell top layer, extremely useful to the treatment of diseases of very difficult treatments such as male baldness, acne, tinea pedis, seborrheic dermatitis.
Claims (2)
1. promote the external agent of cell activation, described reagent obtains by the water-soluble solution of polysaccharide, it is characterized in that, in the overall weight ratio, added krestin, 1～50% pectin, 1～30% glucosan, 1～30% glucose, 1～40% toughness polysaccharide, 1～30% lentinan, 1～50% cyclodextrin and 1～50% the trehalose of 1～50% xyloglucan, 1～50% laminarin and 1～50%.
2. the external agent of promotion cell activation as claimed in claim 1, its feature also be, in the above-mentioned aqueous solution that dissolves polysaccharide, in the overall weight ratio, also added 0.1～1% sodium chloride, 0.1～1% calcium chloride and 0.1～1% potassium chloride.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002113217 | 2002-04-16 | ||
| JP2002113217A JP3885204B2 (en) | 2002-04-16 | 2002-04-16 | External agent for promoting cell activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1451389A CN1451389A (en) | 2003-10-29 |
| CN1240392C true CN1240392C (en) | 2006-02-08 |
Family
ID=29243346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031088236A Expired - Fee Related CN1240392C (en) | 2002-04-16 | 2003-03-26 | Agent for promoting cell activation for external use |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP3885204B2 (en) |
| CN (1) | CN1240392C (en) |
| AU (1) | AU2003213370A1 (en) |
| HK (1) | HK1060048A1 (en) |
| TW (1) | TWI254639B (en) |
| WO (1) | WO2003086421A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005053841A (en) * | 2003-08-05 | 2005-03-03 | Kyouto Biomedical Science:Kk | Skin care preparation for external use |
| CN1285382C (en) * | 2004-12-20 | 2006-11-22 | 凌沛学 | Transmission system of drug for nasal cavity of containing trehalose and byaluronic acid, and preparation method |
| DE102007052380A1 (en) * | 2007-10-31 | 2009-05-07 | Bitop Ag | Osmolyte-containing preparations for use in dry mucous membranes |
| JP5620168B2 (en) * | 2010-06-30 | 2014-11-05 | Ｄｓｐ五協フード＆ケミカル株式会社 | Xyloglucan-cation complex and stabilized composition containing the same |
| CN103239571B (en) * | 2013-05-26 | 2014-09-03 | 广州市云桥生物科技有限公司 | Chinese medicine effective part composition for treating alopecia areata and preparation method thereof |
| JP6313118B2 (en) * | 2014-05-16 | 2018-04-18 | 株式会社Cac | IgE inhibitor |
| WO2017058175A1 (en) * | 2015-09-29 | 2017-04-06 | Kimberly-Clark Worldwide, Inc. | Synergistic composition for maintenance of healthy balance of microflora |
| CN110234325A (en) | 2017-02-28 | 2019-09-13 | 金伯利-克拉克环球有限公司 | For safeguarding the cooperative compositions in a healthy and balanced way of microbiologic population |
| FR3064473B1 (en) * | 2017-04-03 | 2021-02-12 | Basf Beauty Care Solutions France Sas | PROTECTIVE INGREDIENT OF THE BALANCE OF SKIN AND / OR MUCOSAL MICROBIAL FLORA |
| BE1027425B1 (en) * | 2019-07-01 | 2021-02-08 | Aquilon Pharmaceuticals | INHALABLE COMPOSITION INCLUDING CYCLODEXTRIN FOR USE IN THE TREATMENT OF NASAL INFLAMMATIONS |
| WO2023060613A1 (en) * | 2021-10-16 | 2023-04-20 | 南通市巨久新材料科技有限公司 | Peripheral blood mononuclear cell culture dish containing coriolus versicolor mushroom polysaccharide coating layer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03204804A (en) * | 1989-12-28 | 1991-09-06 | Mitsui Toatsu Chem Inc | Skin cosmetic |
| JP2681527B2 (en) * | 1990-02-15 | 1997-11-26 | ジャパンファインケミカル株式会社 | Topical for promoting cell activity |
| DE19710368A1 (en) * | 1997-03-13 | 1998-09-17 | Henkel Kgaa | Use of water-soluble beta-glucans as active ingredients for the production of therapeutic agents for skin treatment |
| JP2002275046A (en) * | 2001-03-23 | 2002-09-25 | Kanebo Ltd | Agent for enhancing barrier against penetration through epidermis, and skin care composition |
-
2002
- 2002-04-16 JP JP2002113217A patent/JP3885204B2/en not_active Expired - Lifetime
-
2003
- 2003-02-20 TW TW092103549A patent/TWI254639B/en not_active IP Right Cessation
- 2003-03-05 WO PCT/JP2003/002536 patent/WO2003086421A1/en active Application Filing
- 2003-03-05 AU AU2003213370A patent/AU2003213370A1/en not_active Abandoned
- 2003-03-26 CN CNB031088236A patent/CN1240392C/en not_active Expired - Fee Related
-
2004
- 2004-04-23 HK HK04102877A patent/HK1060048A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003086421A1 (en) | 2003-10-23 |
| AU2003213370A1 (en) | 2003-10-27 |
| CN1451389A (en) | 2003-10-29 |
| HK1060048A1 (en) | 2004-07-30 |
| JP3885204B2 (en) | 2007-02-21 |
| JP2005289815A (en) | 2005-10-20 |
| TWI254639B (en) | 2006-05-11 |
| TW200407154A (en) | 2004-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1240392C (en) | Agent for promoting cell activation for external use | |
| ES2376330T3 (en) | PHYSIOLOGICALLY ACTIVE COMPOSITION AND PROCEDURE TO PRODUCE THE SAME. | |
| Namba | Maitake D-fraction: healing and preventive potential for cancer | |
| ITUB20154136A1 (en) | Method of production of officinal mushrooms, container for their production and mushrooms so obtained | |
| CN102488278A (en) | Composite fungus nutrient solution with bifunctional health care effect | |
| CA2488011C (en) | External preparations for treating dermatitis | |
| CN1660442A (en) | Transmission system for medicine containing trehalose and hyaluronic acid in use for curing burn and preparing method | |
| CN1615889A (en) | Medicine for treating skin disease | |
| WO2009022221A2 (en) | Composition and method to stimulate growth and defense against pathogens in plants | |
| CN1177044C (en) | Radish chitin bindin and its preparing process | |
| JP2004010605A (en) | Antitumor agent given by using mixture of deacetylated and deoxygenated mushrooms, fermented ganoderma spawn, and other mixture, and health food product, and feed additive containing the agent | |
| US5786343A (en) | Phagocytosis activator compositions and their use | |
| CN1169838C (en) | Acetyl mannan and its preparing method and use | |
| CN1876085A (en) | A Chinese medicinal ointment for promoting wound healing after anal fistula operation and preparation method thereof | |
| CA2485449A1 (en) | Method for preventing mucositis during cancer therapy | |
| JP3890563B2 (en) | Permanent wave agent | |
| CN108785496A (en) | A kind of canker sore sustained release pad pasting and preparation method thereof | |
| US20060079481A1 (en) | Method of treating/preventing mucositis | |
| CN1669472A (en) | Wild Fungus health product and preparation method thereof | |
| CN1075377C (en) | Composite mannosans peptides oral liquor | |
| CN106729672A (en) | A kind of composition for treating upper respiratory tract mucositis and its application | |
| CN1504191A (en) | Cucurbitacin lipsome preparation method and formulation | |
| CN1715297A (en) | Ganoderrma tsugae-proteoglycan and its preparing method and use | |
| CN1715277A (en) | Compound for treating cardiocerebral vascular disease and its preparing method and its use in pharmaceutical field | |
| AU2004218698B2 (en) | Method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1060048 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060208 |